IBR2 is a cell penetrant, potent and specific RAD51 inhibitor that inhibits RAD51-mediated DNA double-strand break repair and enhances cytotoxicity of multiple anticancer agents with disparate biochemical targets including the Bcr-Abl inhibitor imatinib and multiple kinase inhibitor regorafenib. IBR2 disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, reduces ionizing radiation-induced RAD51 foci formation, inhibits cancer cell growth and induces apoptosis.
cell penetrant, potent and specific RAD51 inhibitor
European journal of medicinal chemistry, 96, 196-208 (2015-04-16)
RAD51 recombinase plays a critical role for cancer cell proliferation and survival. Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple negative breast cancers which are often resistant to existing therapeutics. To this end, we have
RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and
The Journal of pharmacology and experimental therapeutics, 364(1), 46-54 (2017-10-25)
Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs. This synthetic lethality can be enhanced by inhibitors of DNA repair. To exploit this potential Achilles heel, we
Questions
Reviews
★★★★★ No rating value
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
